about
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsAn inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoEffects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers.Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride.
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Gliptins: a new class of oral hypoglycaemic agent.
@en
type
label
Gliptins: a new class of oral hypoglycaemic agent.
@en
prefLabel
Gliptins: a new class of oral hypoglycaemic agent.
@en
P356
P1476
Gliptins: a new class of oral hypoglycaemic agent.
@en
P2093
Chowdhury TA
P304
P356
10.1093/QJMED/HCM081
P407
P577
2007-09-19T00:00:00Z